Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Bio-Techne (TECH)

Bio-Techne appoints Dr. Judith Klimovsky to board as independent director

Neutral Impact 2 of 5 leadership Written later

Bio-Techne expanded its board from ten to eleven members on April 24, 2024, and appointed Dr. Judith Klimovsky, currently Executive Vice President and Chief Development Officer at Genmab, as an independent director. The filing also discloses a one-year waiver of the board's mandatory retirement policy for Dr. Roeland Nusse. The change is a board governance update with no financial figures reported.

Key points

  • Dr. Judith Klimovsky appointed as independent director effective April 24, 2024, to the Science and Technology Committee
  • Board temporarily expanded from ten to eleven members, ten of whom are independent
  • Board approved a one-year waiver of mandatory retirement policy for Dr. Roeland Nusse

The filing

CompanyBio-Techne (TECH)
Form8-K, current report
Filed with the SECApr 30, 2024, 4:30 PM ET
Accession number0001558370-24-006279

Items reported: 5.02 Director / Officer Change8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 30, 2024.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.